Driven to overcome the limitations of current treatments for recurrent brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with a purpose to prevent disease progression and improve quality of life for patients with recurrent brain tumors. Extensive clinical expertise informed the design of GammaTile Therapy, and deep medical device experience guides the company.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/31/19 | $10,000,000 | Series A |
BlueStone Venture Partners MedTech Venture Partners  | undisclosed |
| 11/24/20 | $16,000,000 | Series B |
BlueStone Venture Partners MedTech Venture Partners | undisclosed |
| 03/23/23 | $45,000,000 | Series C |
BlueStone Venture Partners Glide Healthcare Partners MedTech Venture Partners MVM Partners | undisclosed |
